Many patients with advanced cancer experience decreased appetite and involuntary weight loss. Weight loss in these patients is rarely recognized, assessed, or actively managed, and thus represents an important unmet need in the clinical management of cancer-associated anorexia and cachexia. Cannabis has been used as an appetite stimulant since 300 AD and presents as a viable therapeutic option for these cachectic patients. A scoping review was conducted to: (1) explore the therapeutic use of cannabis to improve appetite in cancer patients, (2) investigate potential reasons for inconsistency amongst available studies, and (3) identify implications on current practice. Methods: A comprehensive search strategy of four electronic databases (MEDLINE, EMBASE, PsycINFO, and Cochrane Central) was completed and included the literature published between May 1990 to July 2016. Key articles were also hand-searched for further citations, and references from reviews were checked to identify additional studies. Results: A total of 315 articles were identified for screening, and application of inclusion/exclusion criteria resulted in eight studies being included in qualitative synthesis. Assessment resulted eight oral-dosed studies. Small studies (n = 6) suggest positive correlation between tetrohydrocannabinol (THC) and appetite whereas large clinical trials (n = 2) suggest otherwise. Conclusions: Despite anecdotal observations suggesting the potential for cannabis to stimulate appetite, existing studies use various methods of administration and dosing, making it difficult to draw meaningful conclusions. Weak methodological choices in smaller studies have resulted in a high degree of variability in results. Further clinical trials that are well designed and carefully executed are essential to clearly define the role of these agents as appetite stimulants.